Results 301 to 310 of about 170,525 (342)

Gestational Melatonin Supplementation Attenuates Maternal Sleep Deprivation‐Induced Steatohepatitis Susceptibility in Offspring

Cell Proliferation, EarlyView.
Maternal SD during pregnancy enhances the development of diet‐induced NASH in adult offspring of both sexes through an NR4A3‐dependent mechanism, characterised by heightened inflammation and increased apoptosis. Maternal melatonin supplementation effectively alleviates this increased susceptibility to NASH in offspring.
Fei Guo, Zexin Yang, Junsen She, Chen Fang, Yizhi Hu, Hefeng Huang, Ling Gao   +6 more
wiley   +1 more source

Disruption of small intestinal mucosal homeostasis in mice with amiodarone induced steatohepatitis. [PDF]

Sci Rep
Kawauchi S, Horibe S, Tanaka T, Sasaki N, Kunimasa J, Rikitake Y.   +5 more
europepmc   +1 more source

Unveiling the Crucial Nexus: Mitochondrial Quality Control as a Central Driver in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis

Cell Proliferation, EarlyView.
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism‐associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis.
Wenkai Fu, Junqi Wang, Nan Lu, Zhijiang Guo, Sang‐Bing Ong, Yong Gao, Hao Zhou, Xing Chang, Miao Meng   +8 more
wiley   +1 more source

Efficacy and Safety of Vitamin E in Adults With Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Hussaini H, Kaur Dhanjal M, Mohammed Abdul RH, Fadeyi O, Bhatti NA, Rauf MQ, Wei CR, Amin A.   +7 more
europepmc   +1 more source

A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Antipsychotics increase metabolic syndrome (MetSyn) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine‐associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Edward Jackson, Kenneth Koblan, Seth C. Hopkins   +11 more
wiley   +1 more source

Multiparametric Quantitative Ultrasound as a Potential Imaging Biomarker for Noninvasive Detection of Nonalcoholic Steatohepatitis: A Clinical Feasibility Study. [PDF]

Diagnostics (Basel)
Chattopadhyay T, Chan HJ, Le DC, Wang CY, Tai DI, Zhou Z, Tsui PH.   +6 more
europepmc   +1 more source

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population.
Zhuolin Zhou, Nan Gao, Jiaojiao Liu, Xuerong Ma, Zhijuan Ge, Cheng Ji   +5 more
wiley   +1 more source

Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis. [PDF]

J Comp Eff Res
Tapper EB, Ryan T, Zeng N, Carter R, Winer-Jones JP, Bonafede M, Kim Y.   +6 more
europepmc   +1 more source

Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Metabolic bariatric surgery (MBS) improves histological endpoints in steatotic liver disease (SLD), but data on longer‐term clinical outcomes in this population are scarce. Here, we assessed the impact of MBS on hepatic and extrahepatic morbidity and mortality in individuals with SLD.
Weronika Stupalkowska, Alexander Henney, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +4 more
wiley   +1 more source